AirNexis Therapeutics Emerges with $200M and a Late-Stage Respiratory Asset

AirNexis Therapeutics, a newly formed clinical-stage biotechnology company focused on respiratory diseases, has emerged from stealth with a $200 million Series A financing to advance a Phase 2 chronic obstructive pulmonary disease (COPD) candidate.

The company was founded with backing from Frazier Life SciencesDealroom has a profile for this one. Try Dealroom →, which led the Series A round. The proceeds will be used primarily to support the global clinical development of AN01, a drug candidate for COPD, as well as the company’s broader build-out.

AN01 was licensed from China-based Haisco Pharmaceutical Group, which retains rights in mainland China, Hong Kong, Taiwan and Macau.

As part of the transaction, AirNexis paid $40 million upfront and granted Haisco a 19.9% equity stake. The deal includes up to $955 million in potential development and commercial milestones, alongside royalties on future sales outside Haisco’s territories.

The asset is designed to combine bronchodilatory and anti-inflammatory effects, aiming to address both airflow obstruction and inflammation in COPD. Two inhaled formulations, a suspension and a dry powder, are currently being evaluated in Phase 2 trials in China, providing the clinical foundation for AirNexis’s global development plans.

Led by CEO Maria FardisDealroom has a profile for this one. Try Dealroom →, AirNexis is positioning itself as a focused respiratory company built around a late-stage asset with existing clinical data.

Sources:
AirNexis Therapeutics
Business Wire
Fierce Biotech
MarketScreener
FinSMEs
BioSpace

J.V.